SCHEMBL9895975

SCHEMBL9895975

Cn1nnc(-c2ccccc2Cl)c1-c1c[nH]cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.40
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
MAOB P27338 1/20 0.35
KDM5B Q9UGL1 2/20 0.34
PDE2A O00408 2/20 0.34
DCTPP1 Q9H773 1/20 0.34
GRM5 P41594 1/20 0.34
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33
RAB9A P51151 2/20 0.33
PDE10A Q9Y233 2/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895296 0.84 GRM2 (0.35) KDM5BPDE2AGRM5NPC1ALDH1A1
SCHEMBL30697682 0.76 IDO1 (0.48) HSD11B1MAOBKDM5BNPC1ALDH1A1
SCHEMBL9894870 0.72 MAPK14 (0.40)
SCHEMBL14551995 0.72 SLC9A1 (0.47) HSD11B1SMN1; SMN2
SCHEMBL14551997 0.72 SLC9A1 (0.47) HSD11B1SMN1; SMN2
SCHEMBL9895905 0.67 HSD11B1 (0.45) HSD11B1DPP4DPP8DCTPP1NPC1
SCHEMBL14551996 0.64 SLC9A1 (0.39) SMN1; SMN2
SCHEMBL17483475 0.64 DRD4 (0.45) ALDH1A1KDM4E
SCHEMBL9895828 0.64 HSD11B1 (0.41) HSD11B1DPP4DPP8DCTPP1NPC1
SCHEMBL18272794 0.63 TTR (0.49) NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 HSD11B1 525/4885DPP4 2917/4885DPP8 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.